Abstract
Three U.S. National Cancer Institute cooperative group randomized phase 3 trials have demonstrated that the intraperitoneal delivery of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves survival compared to the administration of all agents by the intravenous route. As use of intraperitoneal chemotherapy requires additional resources and expertise beyond that associated with routine intravenous treatment, and unique side effects may be observed (e.g., catheter malfunction, intra-abdominal infection), some have questioned the utility of this approach, despite the documented survival advantage. This review outlines the data supporting intraperitoneal delivery in ovarian cancer, discusses strategies to safely and effectively employ regional therapy, and highlights areas where future trials are required to optimize this novel method for treatment of this malignancy.
Keywords: paclitaxel, Cisplatin, toxicity profile, randomized trials, Southwest Oncology Group
Reviews on Recent Clinical Trials
Title: Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions
Volume: 2 Issue: 3
Author(s): Maurie Markman
Affiliation:
Keywords: paclitaxel, Cisplatin, toxicity profile, randomized trials, Southwest Oncology Group
Abstract: Three U.S. National Cancer Institute cooperative group randomized phase 3 trials have demonstrated that the intraperitoneal delivery of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves survival compared to the administration of all agents by the intravenous route. As use of intraperitoneal chemotherapy requires additional resources and expertise beyond that associated with routine intravenous treatment, and unique side effects may be observed (e.g., catheter malfunction, intra-abdominal infection), some have questioned the utility of this approach, despite the documented survival advantage. This review outlines the data supporting intraperitoneal delivery in ovarian cancer, discusses strategies to safely and effectively employ regional therapy, and highlights areas where future trials are required to optimize this novel method for treatment of this malignancy.
Export Options
About this article
Cite this article as:
Markman Maurie, Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions, Reviews on Recent Clinical Trials 2007; 2 (3) . https://dx.doi.org/10.2174/157488707781662698
DOI https://dx.doi.org/10.2174/157488707781662698 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Oral Precancerous Lesions Show Increased Levels of Glutathione Compared to Cancerous Tissue
Current Nutrition & Food Science The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design The Effects of Mesenchymal Stem Cells in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Editorial (Thematic Issue: Current Overview of Anti-Angiogenic Therapies for Patients with Epithelial Ovarian Cancer)
Current Angiogenesis (Discontinued) Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Modelling DNA Repair Pathways: Recent Advances and Future Directions
Current Pharmaceutical Design Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Current Molecular Pharmacology Recent Developments Towards Podophyllotoxin Congeners as Potential Apoptosis Inducers
Anti-Cancer Agents in Medicinal Chemistry Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Gamma-Amino Butyric Acid Inhibits the Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small Cell Lung Carcinoma
Current Cancer Drug Targets PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design